Stock RAPT RAPT THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq
Other stock markets
 04:00:00 2024-06-12 pm EDT 		5-day change 1st Jan Change
3.55 USD -3.79% Intraday chart for RAPT Therapeutics, Inc. -9.90% -85.71%
May. 14 Wolfe Research Downgrades RAPT Therapeutics to Peer Perform From Outperform MT
May. 10 Guggenheim Downgrades RAPT Therapeutics to Neutral From Buy MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
US Equity Markets Close Higher Thursday as Jobless Claims Climb
MT
Sector Update: Health Care Stocks Higher Late Afternoon
MT
Sector Update: Health Care
MT
RAPT Therapeutics Shares Plunge After Wider Q1 Loss, Closing of Zelnecirnon Trials
MT
RAPT Therapeutics Shares Hit 52-Week Low After Trials Closed
DJ
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
North American Morning Briefing : S&P 500 Futures -2-
DJ
North American Morning Briefing : Nvidia Ignites -2-
DJ
North American Morning Briefing : Stock Futures -2-
DJ
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold
DJ
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event
DJ
FDA puts on hold two Rapt Therapeutics mid-stage drug trials
RE
RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon in Atopic Dermatitis and its Phase 2a Trial in Asthma
CI
RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon to Treat Atopic Dermatitis in Allergy
CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
CI
RAPT Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. RAPT Stock
  4. News RAPT Therapeutics, Inc.
  5. Highlights